Retrospective comparison between a regular and a split-dose protocol of XXXX , @entity900 , and @entity2664 for the treatment of far @entity157 .

@entity1 @entity137 @entity10745 @entity5 @entity2664 @entity900 @entity1398 @entity3 @entity157 @entity715 @entity1487
BACKGROUND: In @entity1 with @entity157 ( @entity157 ), combination chemotherapy using @entity1487 , @entity900 , and @entity2664 (FMP) could achieve a response rate > 20%, but the beneficial effect was compromised by formidable adverse events. Chemotherapy given in a split-dose manner was associated with reduced @entity137 . In this retrospective study, we compared the efficacies and side effects between a regular and a split-dose FMP protocol approved in our medical center. METHODS: From 2005 to 2008, the clinical data of 84 @entity1 with far advanced @entity157 , who had either main @entity715 and/or extrahepatic @entity3 , were reviewed. Of them, 65 were treated by either regular (n = 27) or split-dose (n = 38) FMP and had completed at least one therapeutic course. The remaining 19 @entity1 were untreated. Clinical parameters, therapeutic responses, survivals and adverse events were compared. RESULTS: The median overall survival was 6.0, 5.2, and 1.5 months, respectively, in @entity1 receiving regular FMP, split-dose FMP, and no treatment (regular versus split-dose group, P = 0.447; regular or split-dose versus untreated group; P < 0.0001). @entity1 receiving split-dose treatment had a significantly lower risk of grade 3/4 @entity1398 (51.9 versus 10.5%, P = 0.0005). When the two treated groups were combined, the median overall survival was 10.6 and 3.8 months respectively for @entity1 achieving disease control and progressive disease (P < 0.001). Cox proportion hazard model identified @entity1 -Pugh stage B (hazard ratio [HR], 2.216; P = 0.006), presence of extrahepatic @entity3 (HR, 0.574; P = 0.048), and achievement of disease control (HR, 0.228; P < 0.001) as independent factors associated with overall survival. Logistic regression analysis revealed that @entity10745 virus antibody (odds ratio [OR], 9.219; P = 0.002) @entity5 size (OR, 0.816; P = 0.036), and previous anti- @entity5 therapy (OR, 0.195; P = 0.017) were significantly associated with successful disease control. CONCLUSIONS: Comparable overall survival was observed between @entity1 receiving regular and split-dose FMP therapies. @entity1 receiving split-dose therapy had a significantly lower risk of grade 3/4 @entity1398 . @entity10745 virus antibody, smaller @entity5 size, and absence of previous anti- @entity5 therapy were independent predictors for successful disease control.
